Author

Tianyu Ye

East China University of Science and Technology

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Organism:human· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

Honglin LiiD· 2 shared Jiawen Wang· 2 shared Lili Zhu· 2 shared Na CheniD· 2 shared Rui WangiD· 2 shared Shanshan Ruan· 2 shared Shiliang LiiD· 2 shared Bowen KeiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Honglin LiORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Inhibiting RhoA Activation via GDP-state Stabilization to Relieve Heart Failure

Mengzhu Xue, Yingquan Liang, Zhen Yuan, Xiangning Liu, Longfeng Chang, Yongzhi Wang, Peijia Xu, Tingting Zhang, Hewei Jiang, Zijie Zhao, Jingqiu Liu, Shanshan Ruan, Tianyu Ye, Xuelian Pang, 梅文一, , Honglin Li

This study identifies a compound that inhibits RhoA activation by stabilizing its GDP state, reducing myocardial remodeling and fibrosis in heart failure models.

Circulation Research · Mar 20, 2026Peer-reviewedPharmacology & Toxicology

TRPV4 Inhibition by a Natural Product Mediates Analgesia

Zhen Yuan, Jie Qiu, Shiliang Li, Hanqing Zhao, Na Chen, Shanshan Ruan, Yu Gan, Jiawen Wang, Tianyu Ye, Wenjie Liao, Ziyuan Li, Yanyan Diao, Lili Zhu, Zhenjiang Zhao, Rui Wang, , Bowen Ke

This study identifies AH001 as a potent TRPV4 inhibitor, revealing its mechanism and demonstrating its analgesic effects in pain models.

bioRxiv · Jan 5, 2026 · PreprintBiochemistry

Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer

Huan He, Manzhan Zhang, Xiaoxiao Yang, Shuai He, Xiayu Shi, Feng Hu, Chang Liu, Xingsen Zhang, Na Chen, Xiaoqian Zhu, Leihao Zhang, Tianyu Ye, Rong Zhang, Yanru Yang, Rui Wang, , Shiliang Li

The paper develops ConMeter, a metabolite prediction model, and uses it to design an orally bioavailable RSK4 inhibitor with improved bioavailability and anti-tumor efficacy against esophageal cancer.

bioRxiv · Jun 2, 2025 · PreprintCancer Biology